Medication info
Bodian 25 mg (Empagliflozin)

Bodian 25 mg (Empagliflozin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›25mg / 1 tablet
Manufacturer / importer
Bukwang Pharmaceutical Co., Ltd.
Appearance
Pale yellow oval film-coated tablet
Packaging
PTP - 30 tablets/PTP [10 tablets/PTP x 3]
Approval status
Active

MFDS item code 202105536 · Approved 2021.07.23 · Insurance code 642204850

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this drug is 10 mg once daily, either as monotherapy or as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this drug is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this drug is administered concomitantly with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This drug may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this drug should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this drug well but have a persistent estimated glomerular filtration rate < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This drug should be discontinued if the estimated glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this drug in patients with end-stage renal disease (ESRD) or receiving dialysis, as efficacy is not expected. Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this drug is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. Older adults No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients 75 years of age or older. Initiation of this drug is not recommended in patients 85 years of age or older because clinical experience is limited (see Precautions for Use, section 4. General Precautions).

Ingredients

Manufacturer
Bukwang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

View approved original text

This medication helps adult patients with type 2 diabetes improve blood sugar control alongside dietary and exercise therapy. It can be used alone or in combination with other medications. Particularly for type 2 diabetes patients who are not well controlled, especially those with cardiovascular disease, guidelines regarding the risk of cardiovascular events must be observed. This medication is effectively used to improve blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

The recommended dose of this drug is 10 mg once daily, either as monotherapy or as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this drug is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this drug is administered concomitantly with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This drug may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this drug should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this drug well but have a persistent estimated glomerular filtration rate < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This drug should be discontinued if the estimated glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this drug in patients with end-stage renal disease (ESRD) or receiving dialysis, as efficacy is not expected. Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this drug is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. Older adults No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients 75 years of age or older. Initiation of this drug is not recommended in patients 85 years of age or older because clinical experience is limited (see Precautions for Use, section 4. General Precautions).

Precautions

This medication should not be taken by those who are allergic to the active ingredient or any of the components. It should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Patients with severely impaired kidney function, end-stage renal disease, or those undergoing dialysis should not take this medication. This medication contains lactose and may not be suitable for individuals with genetic issues like lactose intolerance or galactose malabsorption. Patients with slightly impaired kidney function may need dosage adjustments when taking this medication, and use should be discontinued if kidney function deteriorates further. Use with caution in patients with mild to moderate heart failure, and it is not recommended for patients with severe heart failure. There may be a risk of hypoglycemia when taken with other blood sugar-lowering agents such as insulin or sulfonylureas, so dosage adjustments may be necessary. While taking this medication, attention should be paid to potential symptoms such as hypoglycemia, genital and urinary tract infections, increased urination, and signs of dehydration. Particularly in elderly patients or those at risk of fluid loss, monitoring for dehydration and hypotension is important, and temporary discontinuation may be necessary. Serious metabolic abnormalities known as ketoacidosis may occur, and if symptoms are suspected, immediate consultation with a healthcare provider is required. This medication is not recommended during pregnancy, and it is advisable to avoid use while breastfeeding. The safety and efficacy in children and adolescents under 18 years have not been established. Caution is required when driving or operating machinery due to the risk of hypoglycemia. Rare side effects such as lower limb amputations or serious perineal infections have been reported with long-term use, making regular monitoring and observation important. There may be interactions with other medications, so inform your healthcare provider of any other drugs being taken. This medication should be kept out of reach of children and should not be transferred to other containers.

Side effects

  • hypoglycemia
  • vulvovaginitis
  • balanitis and other genital infections
  • urinary tract infections
  • perineal gangrene
  • ketoacidosis
  • pruritus
  • rash
  • urticaria
  • angioedema
Show 11 more
  • decreased fluid volume
  • increased urinary frequency
  • urinary difficulty
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • urosepsis
  • pyelonephritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a sealed container. It is advisable to maintain storage temperatures between 1 degree and 30 degrees Celsius at room temperature to preserve the medication’s effectiveness.

Appearance and packaging

Appearance

Pale yellow oval film-coated tablet

Package unit

PTP - 30 tablets/PTP [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.